Oral Treatment with d-RD2RD2 Impedes Early Disease Mechanisms in SOD1*G93A Transgenic Mice but Does Not Prolong Survival
-
Published:2023-03-23
Issue:4
Volume:11
Page:995
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Wintz Katharina1ORCID, Post Julia1ORCID, Langen Karl-Josef23ORCID, Willbold Dieter14ORCID, Willuweit Antje2ORCID, Kutzsche Janine1ORCID
Affiliation:
1. Institute of Biological Information Processing, Structural Biochemistry (IBI-7), Forschungszentrum Jülich GmbH, 52425 Jülich, Germany 2. Institute of Neuroscience and Medicine, Medical Imaging Physics (INM-4), Forschungszentrum Jülich GmbH, 52425 Jülich, Germany 3. Department of Nuclear Medicine, RWTH Aachen University, 52062 Aachen, Germany 4. Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, 40225 Düsseldorf, Germany
Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting upper and lower motor neurons, thus, progressing to complete muscle loss until the patient dies from respiratory arrest. The disease is not curable, and patients die approximately 2–5 years after diagnosis. Studying the underlying disease mechanisms to get access to new treatment options is, therefore, essential for patients’ benefit. However, so far, only three drugs that alleviate the symptoms have been approved by the U.S. Food and Drug Administration (FDA). A new drug candidate for the treatment of ALS is the all-d-enantiomeric peptide RD2RD2. In this study, we investigated the therapeutic effect of RD2RD2 in two setups. First, we analyzed disease progression and survival in 7 week-old B6.Cg-Tg(SOD1*G93A)1Gur/J mice. Second, we confirmed the result of the survival analysis in the B6SJL-Tg(SOD1*G93A)1Gur/J mouse line. Shortly before disease onset, the mice were treated daily with an oral dose of 50 mg/kg body weight. Treatment with RD2RD2 led to a delayed disease onset and reduced motor phenotype as shown using the SHIRPA test, the splay reflex test, and the pole test, but did not affect survival. In conclusion, RD2RD2 has the ability to delay the onset of symptoms.
Funder
Technology Transfer Fund of the Forschungszentrum Jülich “Portfolio Drug Research” of the “Impuls und Vernetzungs-Fonds der Helmholtzgemeinschaft” Deutsche Forschungsgemeinschaft Helmholtz Association
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference30 articles.
1. Pharmacokinetic properties of a novel d-peptide developed to be therapeutically active against toxic β-amyloid oligomers;Leithold;Pharm. Res.,2016 2. Kutzsche, J., Schemmert, S., Tusche, M., Neddens, J., Rabl, R., Jürgens, D., Brener, O., Willuweit, A., Hutter-Paier, B., and Willbold, D. (2017). Large-scale oral treatment study with the four most promising D3-derivatives for the treatment of Alzheimer’s disease. Molecules, 22. 3. Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: A single and multiple ascending dose phase I study;Kutzsche;Alzheimer’s Dement. Transl. Res. Clin. Interv.,2020 4. Post, J., Kogel, V., Schaffrath, A., Lohmann, P., Shah, N.J., Langen, K.-J., Willbold, D., Willuweit, A., and Kutzsche, J. (2021). A novel anti-inflammatory d-peptide inhibits disease phenotype progression in an ALS mouse model. Molecules, 26. 5. Post, J., Schaffrath, A., Gering, I., Hartwig, S., Lehr, S., Shah, N.J., Langen, K.-J., Willbold, D., Kutzsche, J., and Willuweit, A. (2021). Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1G93A Transgenic Mice. Int. J. Mol. Sci., 22.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|